Thursday, 28 March 2024


Mesoblast files for approval of stem cell product in Japan

07 September 2015 | News | By BioSpectrum Bureau

Mesoblast files for approval of stem cell product in Japan

Tokyo: Australia's regenerative medicine company, Mesoblast Limited has announced that its allogeneic mesenchymal stem cell-based regenerative medicine product JR-031 was recommended for approval at a meeting organized by the Committee on Regenerative Medicine Products and Biological Technology of Pharmaceutical Affairs and Food Sanitation Council of the Japan Ministry of Health, Labour and Welfare. JR-031 is developed by Mesoblast's Japanese partner JCR Pharmaceuticals Co. Ltd.

JCR indicated that marketing approval of JR-031 is anticipated in the near future. JR-031 is a treatment for acute Graft Versus Host Disease (GVHD), a severe complication arising from hematopoietic cell transplants, which JCR has been developing in Japan utilizing technology under a license from Mesoblast. JCR stated that clinical trials demonstrated the efficacy and safety of JR-031 which led to their filing for a marketing approval in September 2014.

Under its agreement with JCR, Mesoblast is entitled to receive milestone payments on JR-031 product regulatory approvals, as well as royalties and other payments at pre-defined thresholds of cumulative net sales.

Mesoblast is conducting an additional open-label phase III study in the United States of its allogeneic MSC product in approximately 60 children, the results of which are expected to support a Biologics License Application to the United States Food and Drug Administration for pediatric product registration.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account